ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061)
Meichen Li, Xue Hou, Jing Chen, Baishen Zhang, Na Wang, Hongyu Han, Likun Chen
Topics & Concepts
ConcomitantAnaplastic lymphoma kinaseMedicineInternal medicineOncologyLung cancerCrizotinibFusion geneGastroenterologyGeneBiologyMalignant pleural effusionBiochemistryLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment